Beam Therapeutics Bennfentes tulajdonlás
Mi az Beam Therapeutics Bennfentes tulajdonlás?
A Bennfentes tulajdonlás az Beam Therapeutics Inc. - 1.90%
Mi a Bennfentes tulajdonlás meghatározása?
A bennfentes tulajdonjog kiszámítása a bennfentesek tulajdonában lévő részvények (részvényesek, akik a vállalat több mint 5% -át, vagy a vállalat tisztségviselőjét vagy igazgatóját birtokolják) teljes létszámával, osztva a teljes részvénykivonással.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Bennfentes tulajdonlás a Health Care szektor a NASDAQ-on cégekben a Beam Therapeutics -hoz képest
Mit csinál Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
bennfentes tulajdonlás -hoz hasonló cégek Beam Therapeutics
- Five Below Inc nak Bennfentes tulajdonlás 1.89% van
- Charter Hall Retail Real Estate Investment Trust nak Bennfentes tulajdonlás 1.89% van
- Coherent Corp nak Bennfentes tulajdonlás 1.89% van
- Oxford Immunotec Global PLC nak Bennfentes tulajdonlás 1.89% van
- Silver Lake Resources nak Bennfentes tulajdonlás 1.90% van
- CryoPort Inc nak Bennfentes tulajdonlás 1.90% van
- Beam Therapeutics nak Bennfentes tulajdonlás 1.90% van
- Murata Manufacturing Co nak Bennfentes tulajdonlás 1.90% van
- Vista Outdoor Inc nak Bennfentes tulajdonlás 1.90% van
- Timbercreek nak Bennfentes tulajdonlás 1.90% van
- iRobot nak Bennfentes tulajdonlás 1.90% van
- Cincinnati nak Bennfentes tulajdonlás 1.90% van
- AMBAC nak Bennfentes tulajdonlás 1.91% van